Cargando…
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online rel...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551675/ https://www.ncbi.nlm.nih.gov/pubmed/32916958 http://dx.doi.org/10.3390/v12091006 |
_version_ | 1783593234860081152 |
---|---|
author | Tzou, Philip L. Tao, Kaiming Nouhin, Janin Rhee, Soo-Yon Hu, Benjamin D. Pai, Shruti Parkin, Neil Shafer, Robert W. |
author_facet | Tzou, Philip L. Tao, Kaiming Nouhin, Janin Rhee, Soo-Yon Hu, Benjamin D. Pai, Shruti Parkin, Neil Shafer, Robert W. |
author_sort | Tzou, Philip L. |
collection | PubMed |
description | Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development. |
format | Online Article Text |
id | pubmed-7551675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75516752020-10-14 Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds Tzou, Philip L. Tao, Kaiming Nouhin, Janin Rhee, Soo-Yon Hu, Benjamin D. Pai, Shruti Parkin, Neil Shafer, Robert W. Viruses Article Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development. MDPI 2020-09-09 /pmc/articles/PMC7551675/ /pubmed/32916958 http://dx.doi.org/10.3390/v12091006 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tzou, Philip L. Tao, Kaiming Nouhin, Janin Rhee, Soo-Yon Hu, Benjamin D. Pai, Shruti Parkin, Neil Shafer, Robert W. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title_full | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title_fullStr | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title_full_unstemmed | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title_short | Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds |
title_sort | coronavirus antiviral research database (cov-rdb): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551675/ https://www.ncbi.nlm.nih.gov/pubmed/32916958 http://dx.doi.org/10.3390/v12091006 |
work_keys_str_mv | AT tzouphilipl coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT taokaiming coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT nouhinjanin coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT rheesooyon coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT hubenjamind coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT paishruti coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT parkinneil coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds AT shaferrobertw coronavirusantiviralresearchdatabasecovrdbanonlinedatabasedesignedtofacilitatecomparisonsbetweencandidateanticoronaviruscompounds |